NurseJet
Back to Discover
Systematic ReviewResearchMedication SafetyPatient Education

Semaglutide reduced weight in adults without diabetes across nine trials

International journal of obesity (2005) (PubMed)Aug 29, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A meta-analysis of placebo-controlled trials found subcutaneous semaglutide reduced body weight, waist circumference, and C-reactive protein in adults with overweight or obesity without diabetes.

What NurseJet pulled from the source

Nine randomized trials included 6,239 participants. Compared with placebo, semaglutide reduced body weight by a mean 12.04 percentage points and waist circumference by 9.36 cm; serious adverse-event risk did not differ significantly (RR 1.12, 95% CI 0.76-1.65). Longer-term efficacy and safety remain uncertain.

Why this matters for nurses

Nurses increasingly encounter semaglutide in weight-management care. The findings help frame expected population-level benefit while preserving medication reconciliation, adverse-effect assessment, dose-specific teaching, and realistic discussion of longer-term uncertainty.

Bedside takeaway

Pair weight-response monitoring with dose-specific medication reconciliation, tolerance assessment, and realistic long-term uncertainty.

How This Applies in Practice

Use this when: Caring for an adult prescribed subcutaneous semaglutide for weight management without diabetes.

On your shift

  • Reconcile the exact product, current dose, titration schedule, indication, last administration, and other medications.
  • Assess tolerance, hydration and nutrition, weight trend, administration technique, and barriers to follow-up.
  • Escalate concerning symptoms, dosing errors, or inability to maintain intake through the prescribing team's approved pathway.
Keep in mind: Do not infer an individual response from pooled averages or change dosing independently. Follow facility policy and provider orders.

Key takeaways

  • The review included nine randomized placebo-controlled trials and 6,239 adults without diabetes.
  • Mean percentage body-weight change favored semaglutide by 12.04 percentage points.
  • Waist circumference and C-reactive protein also decreased relative to placebo.
  • Serious adverse events did not differ significantly, but the review called for longer-term safety and efficacy data.

Practice implications

  • Confirm the product, prescribed dose and titration, indication, administration technique, missed-dose plan, tolerance, and follow-up. Report concerning symptoms or inability to maintain hydration and nutrition through the prescribing team's established pathway.

Limitations & cautions

  • The abstract reports nine placebo-controlled trials but does not establish long-term outcomes across all clinical populations. The serious-adverse-event estimate was imprecise, and pooled efficacy should not be used to predict an individual's response or support an unprescribed dose change.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

International journal of obesity (2005) (PubMed)

International journal of obesity (2005) (PubMed). Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42668312/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Neurosurgical review (PubMed)

A systematic review and meta-analysis of 14 studies comprising 7,981 patients found extending single-agent antibiotic prophylaxis beyond one day did not reduce postoperative meningitis after endoscopic endonasal skull base surgery, whereas intraoperative CSF leak significantly increased infection risk.

Med-SurgAI summaryReview source

Anesthesia and analgesia (PubMed)

A meta-analysis of 25 randomized controlled trials with 3,344 surgical patients found perioperative ketamine and esketamine were associated with reduced postoperative delirium between days 2 and 7, but significantly increased postoperative dizziness.

GeriatricsMed-SurgAI summaryReview source

Western journal of nursing research (PubMed)

A systematic review and meta-analysis of 38 studies including 19,033 patients identified clinical severity scales—specifically Modified Fisher grade and Fisher grade—and hemodynamic status as the strongest predictors of cerebral vasospasm following subarachnoid hemorrhage.

EmergencyICUAI summaryReview source